Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. operates in Biotech with headquarters in see investor materials (founded see company history). The headline market cap of $0B reflects how public markets are pricing the equity right now; it can swing on rates, sector sentiment, and a handful of product cycles. Revenue of not modeled on this page is shown as a coarse annualized snapshot for orientation—always compare to the latest audited financials.

From a capital-allocation lens, we watch how reinvestment (R&D, capex, M&A) maps to returns and balance-sheet flexibility. A wide gap between revenue growth and multiple expansion often signals shifting expectations about moat durability, regulation, or geographic mix. Where we publish charts, they are built from the site's structured history fields and may be interpolated when filings are sparse—see methodology for limitations.

Competitive benchmarking on this page uses linked peers when available; treat it as a starting point for industry mapping, not a buy/sell screen. Ticker FHTX is displayed for convenience; verify exchange codes before trading.

Editorial note: this section is authored in-house to explain how we connect metrics to meaning. It is updated when material fundamentals change; report issues on corrections.